

John J. Tobin and Gary Walsh

# Medical Product Regulatory Affairs

Pharmaceuticals, Diagnostics, Medical Devices

Second Edition





## **Medical Product Regulatory Affairs**



# **Medical Product Regulatory Affairs**

Pharmaceuticals, Diagnostics, Medical Devices

Second Edition

*John J. Tobin*

*Gary Walsh*

## Authors

### **Dr. John J. Tobin**

ChemHaz Solutions  
Laccaroe, Feakle  
Clare County  
Ireland

### **Prof. Gary Walsh**

Chair, Industrial Biotechnology  
Chemical and Environmental  
Sciences Department  
University of Limerick  
Castletroy, Limerick City  
Ireland

**Cover:** © mayamaya/Shutterstock

■ All books published by **WILEY-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

### **Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2024 WILEY-VCH GmbH, Boschstraße 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Print ISBN:** 978-3-527-33326-4

**ePDF ISBN:** 978-3-527-68897-5

**ePub ISBN:** 978-3-527-68898-2

**Typesetting** Straive, Chennai, India

## Contents

<b>1</b>	<b>The Aims and Structure of Regulations</b>	<b>1</b>
1.1	Introduction	1
1.2	Purpose and Principles of Regulation	1
1.3	The Legal Framework for Regulation	3
1.3.1	National Legislative Process	3
1.3.2	EU Legislative Process	4
1.3.3	Working with Legal Texts	6
1.3.4	Guidance Documents	7
1.3.5	Pharmacopoeia	7
1.4	Basic Legislation	7
1.4.1	EU Legislation	7
1.4.2	US Legislation	12
1.5	Scope of the Legislation	15
1.6	Chapter Review	20
1.7	Further Reading	21
<b>2</b>	<b>Regulatory Strategy</b>	<b>23</b>
2.1	Chapter Introduction	23
2.2	Basic Regulatory Strategy	23
2.2.1	Product Development	23
2.2.2	Product Manufacture	23
2.2.3	Market Vigilance	24
2.3	Quality Assurance Systems	25
2.3.1	Personnel	25
2.3.2	Documentation	25
2.3.3	Facilities and Equipment	26
2.3.4	Corrective and Preventative Action	27
2.4	Validation	27
2.5	Regulatory Bodies	29

- 2.5.1 European Commission 29
- 2.5.2 The EMA 30
- 2.5.3 National Competent Authorities 32
- 2.5.4 Notified Bodies 34
- 2.5.5 The FDA 35
- 2.5.6 US Department of Agriculture (USDA) 39
- 2.5.7 Pharmacopoeia Authorities 39
- 2.6 International Harmonisation Bodies 40
- 2.7 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 41
  - 2.7.1 VICH 43
  - 2.7.2 The International Medical Device Regulators Forum (IMDRF) 43
- 2.8 Pharmaceutical Inspection Cooperation Scheme (PICS) 44
- 2.9 The World Health Organisation (WHO) 45
- 2.10 Chapter Review 45
- 2.11 Further Reading 46

### **3 Drug Discovery, Classification and Early Stage Development 47**

- 3.1 Chapter Introduction 47
- 3.2 Drug Categorisation 47
  - 3.2.1 Prescription Status 47
  - 3.2.2 Physical Properties 48
  - 3.2.3 Mode of Action 48
  - 3.2.4 Therapeutic Use 49
- 3.3 Drug Discovery 51
  - 3.3.1 Target Discovery and Validation 52
  - 3.3.2 Lead Discovery, Validation and Optimisation 57
- 3.4 Drug Development 58
  - 3.4.1 Manufacture and Control 59
- 3.5 Drug Delivery 59
  - 3.5.1 Location 60
  - 3.5.2 Drug Characteristics 60
  - 3.5.3 Speed and Duration of Therapeutic Effect 62
  - 3.5.4 Stability 63
- 3.6 Chapter Review 63
- 3.7 Further Reading 63

### **4 Non-clinical Studies 65**

- 4.1 Chapter Introduction 65
- 4.2 Non-clinical Study Objectives and Timing 65
- 4.3 Pharmacological Studies 69



4.3.1	Pharmacodynamic Studies	70
4.3.2	Pharmacokinetic/Toxicokinetic Studies	72
4.4	Bioavailability and Bioequivalence	73
4.5	Toxicology Studies	74
4.5.1	Toxicity Studies	74
4.5.2	Genotoxicity Studies	75
4.5.3	Carcinogenicity Studies	76
4.5.4	Reproductive Toxicology Studies	76
4.6	Chemistry, Manufacturing and Control Development (CMC)	77
4.7	Quality by Design (QbD)	77
4.8	Quality of Biotech Products	78
4.8.1	Stability Studies	78
4.9	Good Laboratory Practice (GLP)	78
4.10	Chapter Review	80
4.11	Further Reading	83
<b>5</b>	<b>Clinical Trials</b>	<b>85</b>
5.1	Chapter Introduction	85
5.2	Clinical Trials	85
5.2.1	Phase I Trials	86
5.2.2	Phase II Trials	86
5.2.3	Phase III Trials	87
5.3	Clinical Trial Design	88
5.4	Good Clinical Practice	90
5.5	Clinical Trials in the EU	90
5.5.1	Sponsor	93
5.5.2	Investigator's Brochure (IB)	93
5.5.3	Investigator	94
5.5.4	Trial Protocol	94
5.5.5	Investigational Medicinal Product Dossier (IMPD)	94
5.5.6	Informed Consent	94
5.5.7	Manufacture of Investigational Medicinal Product	95
5.5.8	Clinical Trial Authorisation	95
5.5.9	Independent Ethics Committee Opinion	96
5.5.10	Amendments to Clinical Trials	97
5.5.11	Case Report Forms (CRFs)	97
5.5.12	Adverse Event Reporting	97
5.5.13	Annual Safety Report	98
5.5.14	Monitoring of Trials	98
5.5.15	End of Trial	98
5.5.16	Trial Master File	98
5.6	Clinical Trials in the US	100

5.6.1	Investigational New Drug Application (IND)	100
5.6.2	Institutional Review Board (IRB)	103
5.6.3	Communication with the FDA	104
5.6.4	Labelling of Investigational Drugs	105
5.6.5	Registry of Clinical Trial Information	105
5.7	Chapter Review	105
5.8	Further Reading	106
<b>6</b>	<b>Marketing Authorisation</b>	<b>109</b>
6.1	Chapter Introduction	109
6.2	The Application Dossier	109
6.3	CTD	110
6.3.1	Module Structure	112
6.3.2	Module 3 – Quality	113
6.3.3	Drug Master Files	116
6.3.4	Module 4 – Non-clinical Study Reports	116
6.3.5	Module 5 – Clinical Study Reports	116
6.3.6	Module 2 – Summaries	118
6.3.7	Module I – Region Specific	120
6.3.8	Module 1 – EU	121
6.3.9	Module 1 – US	123
6.4	Submission and Review Process in the EU	127
6.4.1	Union Authorisation	128
6.4.2	Scientific Evaluation Process	129
6.4.3	Decision Making Process	130
6.4.4	National Authorisations	132
6.4.5	Decentralised Procedure	132
6.4.6	Mutual Recognition Procedure	134
6.4.7	Plasma Master Files and Vaccine Antigen Master Files	134
6.5	Submission and Review Process in the US	134
6.6	Chapter Review	138
6.7	Further Reading	138
<b>7</b>	<b>Authorisation of Veterinary Medicines</b>	<b>139</b>
7.1	Chapter Introduction	139
7.2	Overview of Development Process for Veterinary Medicines	139
7.2.1	Pre-clinical Studies	140
7.2.2	Clinical Trials	141
7.2.3	Good Clinical Practices	141
7.3	Authorisation of Clinical Trials in the EU	145
7.4	Authorisation of Clinical Trials in the US	146

7.5	Maximum Residue Limits (MRLs)	147
7.6	Authorisation of Veterinary Medicines in the EU	149
7.6.1	Applications to Establish MRLs	149
7.6.2	Review of Applications and Establishment of MRLs	152
7.6.3	Marketing Authorisations	156
7.6.4	Presentation of the Dossier	156
7.7	Approval of Veterinary Medicines in the US	158
7.7.1	New Animal Drug Application (NADA)	158
7.7.2	Approval of Veterinary Biological Products	163
7.8	Chapter Review	164
7.9	Further Reading	164
<b>8</b>	<b>Variations to the Drug Authorisation Process</b>	<b>165</b>
8.1	Chapter Introduction	165
8.2	Provisions in Support of Special Drug Applications	165
8.2.1	Orphan Drugs	165
8.2.2	Paediatric Applications	167
8.3	Accelerated Access to New Drug Therapies	170
8.3.1	EMA Accelerated Review and Conditional Marketing Routes	170
8.3.2	EU Compassionate Use	171
8.3.3	Expedited Pathways in the US	171
8.3.4	Expanded Access and Emergency Use Authorization (EUA)	174
8.4	Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible	175
8.5	Animal Drugs for Minor Use and Minor Species	176
8.5.1	Conditional Approval	176
8.5.2	Indexing	176
8.5.3	Designation	176
8.6	Special Provisions to Facilitate Access to Drugs for Animal Treatment in the EU	177
8.7	Changes to an Authorised Drug	177
8.8	EU System for Processing Changes	177
8.8.1	Extension Applications	178
8.8.2	Major Variation (Type II)	178
8.8.3	Minor Variation (Type IA or IB)	179
8.9	Processing Changes in the US	179
8.9.1	Manufacturing Change Supplements	180
8.9.2	Major Changes	180
8.9.3	Moderate Changes	180
8.9.4	Minor Changes	181
8.10	Authorisation of Generic Drugs	181

8.10.1	EU Regulations	181
8.10.2	US Regulations	182
8.11	Biosimilars	183
8.11.1	EU Regulations	184
8.11.2	US Regulations	185
8.12	Reference Drug Exclusivity	189
8.13	Other Authorisation Procedures	191
8.13.1	Well-Established Medical Use Products	191
8.13.2	Combination Products	191
8.13.3	Homeopathic Medicines	192
8.13.4	Traditional Herbal Medicines	192
8.13.5	US Regulation of OTC Drugs	193
8.14	Chapter Review	193
8.15	Further Reading	194
<b>9</b>	<b>Medical Devices</b>	<b>195</b>
9.1	Chapter Introduction	195
9.2	Regulatory Strategy for Medical Devices in the EU	195
9.2.1	Use of Standards to Establish Conformity	200
9.2.2	Classification of Devices	201
9.3	Regulatory Strategy for Medical Devices in the US	210
9.3.1	Classification of Devices	210
9.3.1.1	Class I	211
9.3.1.2	Class II	211
9.3.1.3	Class III	211
9.3.2	Classification of New Devices	212
9.4	Development of Devices	212
9.4.1	Design Controls	213
9.4.2	Design and Development Planning	214
9.4.3	Design Input	214
9.4.4	Design Output	216
9.4.5	Design Verification and Design Validation	216
9.4.6	Design Review	217
9.4.7	Risk Analysis	218
9.4.8	Design Changes	218
9.5	Chapter Review	218
9.6	Further Reading	219
<b>10</b>	<b>Authorisation of Medical Devices</b>	<b>221</b>
10.1	Chapter Introduction	221
10.2	Evaluation of Medical Devices in Europe	221
10.2.1	Clinical Evaluation	221

10.2.2	Clinical Investigations	222
10.2.3	Performance Evaluation of IVDs	225
10.2.4	Performance Studies of IVDs	225
10.3	Evaluation of Medical Devices in the US	226
10.3.1	Exempted Investigations	227
10.3.2	Abbreviated Requirement Investigations	227
10.3.3	IDE Investigations	227
10.3.4	Labelling of Devices for Investigational Use	229
10.4	Placing of Devices on the Market in the EU	230
10.4.1	Designation of Notified Bodies	230
10.4.2	Conformity Assessment Procedures	232
10.4.2.1	Conformity Assessment Based on a Quality Management System and Assessment of Technical Documentation	233
10.4.2.2	EU Type-Examination	235
10.4.2.3	Production Quality Assurance	235
10.4.2.4	EU Verification	235
10.4.2.5	EU (Self) Declaration of Conformity	236
10.4.3	Technical Documentation	236
10.4.4	Labelling Requirements	236
10.4.5	Registration of Economic Operators and Devices	238
10.5	Placing of Devices on the Market in the US	238
10.5.1	510(k) Pre-market Notification	239
10.5.2	Traditional 510(k)	239
10.5.3	Abbreviated 510(k)	239
10.5.4	Special 510(k)	239
10.5.5	<i>De Novo</i> 510(k)	240
10.5.6	Notification and Review Procedures	240
10.5.7	Pre-market Approval (PMA)	240
10.5.8	Changes to a PMA-Approved Device	241
10.5.9	Humanitarian Use Devices (HUDs)	243
10.5.10	Labelling of Devices	243
10.6	Chapter Review	243
10.7	Further Reading	244
<b>11</b>	<b>Good Manufacturing Practice (GMP)</b>	<b>245</b>
11.1	Chapter Introduction	245
11.2	Drug GMP Regulations and Guidance	245
11.3	Essential GMP Requirements	248
11.3.1	Quality Assurance System	248
11.3.2	Personnel	248
11.3.3	Premises and Equipment	249
11.3.4	Documentation	257

11.3.5	Production	257
11.3.6	Quality Control	258
11.3.7	Work Contracted Out	259
11.3.8	Complaints, Product Recall and Emergency Un-blinding	259
11.3.9	Self-inspection	259
11.4	Validation	260
11.4.1	Facilities and Equipment Validation	261
11.4.2	Process Validation	262
11.4.3	Computer Systems Validation	262
11.4.4	Methods Validation	265
11.4.5	Cleaning Validation	266
11.4.6	Validation of Sterilisation Procedures	267
11.4.7	Water Purification System Validation	268
11.5	GMP Requirements for Devices	268
11.6	Chapter Review	273
11.7	Further Reading	273
<b>12</b>	<b>Oversight and Vigilance</b>	<b>275</b>
12.1	Chapter Introduction	275
12.2	Registration of Manufacturers and Other Entities	275
12.3	Manufacturing Authorisation of Medicinal Products in the EU	275
12.3.1	Wholesale Distribution of Medicinal Products	276
12.3.2	Registration of Economic Operators for Medical Devices on the EU market	278
12.4	Registration of Producers of Drugs and Devices in the US	278
12.5	Additional Licensing Requirements	279
12.6	Inspections	279
12.6.1	Inspection Techniques	280
12.6.2	Audit Findings and Consequences	286
12.7	Market Vigilance and Oversight of Drugs	289
12.7.1	Pharmacovigilance in the EU	289
12.7.2	Pharmacovigilance Risk Assessment Committee (PRAC) and the EudraVigilance System	290
12.7.3	Pharmacovigilance and Marketing Authorisation Holders	293
12.7.4	Pharmacovigilance Inspections and Audits	294
12.7.5	Renewal of Marketing Authorisations	295
12.7.6	Pharmacovigilance and Reporting in the US	295
12.7.7	Periodic Reports	296
12.8	Advertising and Promotion	297

12.9	Market Vigilance and Oversight of Devices	298
12.9.1	Market Vigilance in the EU	298
12.9.2	Medical Device Vigilance in the US	299
12.9.3	Medical Device Reporting	299
12.9.4	Reports of Corrections and Removals	300
12.9.5	Post-market Surveillance	302
12.10	Chapter Review	303
12.11	Further Reading	303
	<b>Index</b>	<b>305</b>





# 1

## The Aims and Structure of Regulations

### 1.1 Introduction

Drugs and medical devices are among the most stringently regulated products in the developed world. This chapter introduces you to the basic principles and concepts behind the regulations so that you can fully appreciate the importance of compliance. The chapter then looks at the general legislative framework that is used to create regulations and identifies the core legal texts that are used to regulate such products in the European Union (EU) and the United States of America (US). Finally, the chapter examines the legal definitions of drugs and medical devices, which are central to determining the scope of the regulations.

### 1.2 Purpose and Principles of Regulation

The fundamental purpose of regulation is the protection of public health.

Although this appears a very simple goal, its attainment has required the development of extensive and complex regulations. As a newcomer to the subject, you may find some of the regulations cumbersome and almost overbearing. However, as you study this chapter, you will see that many of the landmark advances in regulatory development were triggered by adverse incidents. Thus, you should accept the current regulations as representing the distilled wisdom of past experience.

To achieve their goal, the regulations rely on a number of core principles and concepts.

- Safety
- Efficacy
- Purpose
- Risk/benefit
- Quality

**Product safety** is an underlying principle for all products. Ideally, the product should do no harm. Thus, the regulations require that the developer or manufacturer must take appropriate steps to demonstrate and ensure the safety of the product under development.


Obviously, for it to be worthwhile, the product must also do some good. Hence, the principle of **efficacy** or effectiveness has become another cornerstone in achieving the goal of regulation. To evaluate effectiveness, you must also consider the purpose of the product as expressed in either an *indications for use* statement in the case of drugs or *intended use* statement in the case of medical devices. As discussed in Section 1.6, and later in Sections 9.3 and 9.4, intended use statements are also vital in determining how some products are regulated in the first place, which in turn dictates the level of scrutiny to which they may be subjected.

In the case of most simple medical devices (a hospital bed for example) it will be relatively straightforward for you to conclude that the product is safe and effective in achieving its intended purpose. However, for more complicated medical devices and many drugs, the situation may not be so clear-cut. Most drugs have some side effects. These can range from mild to quite severe. Additionally, many drugs show considerable variation in effectiveness within the patient population that the drug is intended to treat. Thus, you will have to apply the concept of **Risk to Benefit** when making a judgement as to whether a product should be marketed and as to what limitations, if any, should apply to its use. Looking at it from a regulatory stance you must ask the questions, do the benefits outweigh the risks, and in the overall balance does the product enhance public health?

Consideration of the following examples of existing drug products may help you to understand this point. Chemotherapy drugs used to fight cancer are known to have significant side effects including severe nausea and hair loss, while they are rarely effective in all cancer patients. However, despite their limitations, they still provide a vital element in the fight against cancer as they can contribute to the cure of what could otherwise be a fatal disease.

Risk to benefit has also been a subject of debate surrounding the administration of vaccines. In recent years, concerns have been raised in the popular press about possible side effects from the MMR vaccine, which is given to infants to guard against Measles, Mumps and Rubella. This led to a drop in the levels of vaccination. However, the advice from health professionals continues to be in favour of vaccination, because even if the claimed side effects were shown to be true, failure to vaccinate would still statistically pose a greater health risk due to the detrimental effects of the diseases themselves. Most recently risk-benefit analysis has guided regulators in providing advice regarding the rollout of vaccines against SARS-COV-2 in efforts to control and mitigate the effects of the COVID-19 pandemic. It was noted that the severity of the disease, which can prove fatal, increased with age while a rare side effect of blood clots, which could also result in death, was observed as some of the vaccines were rolled out. Considering limitations in the availability of vaccines and the urgency to get populations vaccinated, regulators used risk-benefit analysis to guide them in advising which vaccines to use on different population cohorts.

The final element which regulations address is **quality**. Safety and fitness for purpose, as discussed above, are two of the characteristics that you would associate with a quality product. However, these characteristics alone would not describe a quality product. For any product or service to be considered quality you would also expect it to be reliable and consistent. Additionally, in the context of medical products, quality means a requirement to demonstrate conformance to agreed



**Figure 1.1** Regulatory principles.

specifications or applicable standards for content, purity and stability. Many organisations, from manufacturers to service providers, voluntarily apply quality assurance systems to more effectively meet their customers' needs on a consistent basis. However, this is not a voluntary option for manufacturers of drugs and potential high-risk medical devices. Such enterprises are legally required to apply an appropriate quality assurance system, the specifics of which are, for the most part, defined in regulations. These basic principles are illustrated in Figure 1.1.

## 1.3 The Legal Framework for Regulation

As you will encounter many different types of legal instruments in the course of this book, it is worthwhile that you take some time to understand the basic principles on which such instruments are constructed. Several are discussed here, with links provided to appropriate websites in the further reading section of this chapter. Many of these legal instruments will be considered in detail in further chapters.

### 1.3.1 National Legislative Process

In a modern constitutional democracy, laws are created via a hierarchical legislative process. You will find the principal legal principles laid down in a constitution,

which derives its legitimacy directly from the will of the people and can only be amended via referendum. It sets out your basic rights as an individual in the state and establishes a system of governance that provides for legislative, executive and judicial branches of government.

The legislature consists of elected representatives who act on behalf of the people in a legislative assembly (houses of parliament) and have the power to propose new legislation in the form of a Bill. In practice, most legislation is introduced by Government Ministers in their role as the political heads of the executive branch of government. After a number of stages during which it is scrutinised and debated, the Bill, if acceptable, is approved by majority vote in the houses of parliament. It then proceeds to become an Act once it is signed into law by the head of state.


An Act establishes the broad legal requirements pertaining to a particular topic and grants powers of enforcement to the relevant Government Minister. An Act will also usually confer power on the Minister to issue further detailed regulations that enable practical application and enforcement of the Act. Such regulations are issued in the form of Statutory Instruments in Europe or additions to the Code of Federal Regulations (CFR) in the US. The overall legislative process is illustrated in Figure 1.2.

In summary, you will find that Acts contain the broad legal principles whereas you are more likely to find the detailed technical requirements of the law in the regulations.

The executive branch of government is responsible for executing the law. It consists of the ministerial heads of each government department together with the civil service and all other state agencies and authorities empowered to administer and enforce the law. The judicial branch function as independent guardians of your rights and adjudicate on whether the executive have, in applying the law, overstepped the powers granted to them via the constitution, acts or regulations.

### 1.3.2 EU Legislative Process

A different system applies to the creation of legislation at EU level. The EU is based on a series of treaties between member states, which are comparable to constitutional law at national level. Three institutions are involved in the creation of EU law: The European Commission, The Council of the European Union and The European Parliament. The European Commission acts as the executive body and is headed by Commissioners nominated by the member states. It is primarily



**Figure 1.2** National legislative process.

responsible for preparing and presenting legislative proposals. Responsibility for approval of the proposals is shared between the Council, which consists of the government Ministers from each member state, the European Parliament, which contains directly elected representatives, and the Commission. Different mechanisms for distribution of power between the institutions are used, depending on the subject matter of the legislation. Approval of basic legislative measures requires the involvement of the Council and the Parliament, whereas the Commission are empowered to approve provisions of a technical or administrative nature. The issuing authority will always be identified in the title of the document.

Binding EU legislation is issued in the form of Regulations, Directives and Decisions.

An EU Regulation is directly applicable in each member state, without the need for transposition into national legislation. However, you will find that some supplementary national legislation is usually required so as to establish penalties and powers of enforcement at national level.

Directives, on the other hand, are addressed to member states and require that they enact national legislation so as to achieve the objectives of the directives. Thus, a directive allows flexibility in how national legislation is enacted. In practice, national legislation will frequently refer you back to the directive, particularly when a directive contains large amounts of detailed technical requirements.


Note: Because of issues of divergent interpretation of some Directives by Member States, there is a tendency to replace Directives by Regulations in recent legislative updates.

Regulations and Directives use a similar structure.

- You will start by reading statements citing the legal basis for the document and the reasoning behind its creation ('whereas' statements).
- Then you will find the fundamental legal requirements set out in a series of articles.
- Finally, where applicable, you will find detailed technical requirements in one or more Annexes.

In a sense, the articles equate to what you might expect to find in an Act at national level, while the content of Annexes would be more akin to what would be placed in regulations. There is also a parallel in terms of authorisation, in that amendments to the articles usually require the approval of the political institutions, whereas adaptation of the Annexes to technical progress is possible via a decision of the Commission, functioning as the executive body. You can see this in practice by just looking at the title of each instrument that you read.

The final legal instrument is a Decision. A decision focuses on an individual measure and is directly binding in its entirety on the specific individuals or entities to whom it is addressed. The Commission uses Decisions to issue marketing authorisations for approval of new drugs granted under a 'centralised' procedure (Chapter 6). Figure 1.3 summarises the relationship between various legal instruments used in Europe.



**Figure 1.3** The relationship between National and EU legal instruments and the flow of legislative authority.

### 1.3.3 Working with Legal Texts

It is advisable that for the most part you use the EU documents as your primary source of legislation. There are a number of benefits to doing this:

- You get both the principal legal requirements (The Articles) and the technical detail (The Annexes) in one document. As mentioned above national legislation may just transpose the Articles, and you may have to refer back to the directive for the technical Annexes.
- National legislation is moulded by Directives, and new national legislation is invariably a response to EU initiatives.
- Most products are targeted at international rather than just national markets. Once you comply with the requirements of the directive, national legislation may not impose additional requirements other than as provided for in the directive (language requirements, etc.).

However, when working with Directives or Regulations, you need to be careful about updates. Once a 'base' Directive or Regulation is established, subsequent Directives or Regulations can be issued to amend one or more of the Articles of the 'base' text, or to adapt the Annexes to technical progress. This makes the original section of the base Directive or Regulation no longer applicable. To help you work with the legislation, the EU prepares consolidated texts. However, it is only the Directives or Regulations as published in the *Official Journal of the European Community* that have legal standing. Occasionally, in the interests of clarity, the EU will start afresh and recast a new 'base' Directive or Regulation incorporating all previous amendments.

### 1.3.4 Guidance Documents

In addition to the legal texts, you will also encounter guidance documents issued by the agencies involved in application and enforcement of legislation and other interested parties.

These are intended to help you understand what the law requires and to provide you with solutions as to what to do to meet the requirements. There is considerable variety in the type of guidance documents available. Some documents are used to describe specific requirements in precise detail, such as the procedures for making regulatory submissions, whereas other documents will tend to be more general in nature and may just raise points to consider or suggested approaches. In practice, they are of great practical value and give a very good insight into what an agency is expecting in terms of application of regulations. Guidance documents, adopted pursuant to specific requirements contained in EU Regulations or Directives, have a derived legal status. However, other guidance does not have formal legal status and may not be taken as an interpretation of what the law requires, as such a determination is the preserve of the judiciary. Irrespective of its status, industry are advised to follow all relevant guidance, so as to facilitate smoother interaction with the regulatory authorities, and avoid having to justify alternative approaches that may otherwise be used.

### 1.3.5 Pharmacopoeia

Pharmacopoeial publications provide a final important source of information for the pharmaceutical industry, regulatory authorities and the healthcare professions. These are concerned with establishing quality standards. They contain monographs that define specifications for the purity and identity of established pharmaceutical ingredients, both active and non-active, together with recognised analytical methods that may be used to evaluate them. The most relevant are the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph.Eur).

## 1.4 Basic Legislation

### 1.4.1 EU Legislation

The core legislation governing the regulation of drugs in the EU is contained in three 'base' legal instruments, which provide the framework for regulation of medicines at both national and community level. These are:

---

Dir. 2001/83/EC	Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
Reg. EC/726/2004	Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency
Reg. EU/2019/6	Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC

---

The human medicines directive replaced an original directive and its amendments that dated back to 1965 (65/65/EEC). This original directive was prompted by a determination to prevent a recurrence of a catastrophe that came to light in the early 1960s, when it was concluded that the birth of thousands of babies with limb deformities was as a result of their mothers having taken a new sedative drug, Thalidomide, during pregnancy. This proved to be a cathartic event as it exposed the limitations in the regulatory measures that existed at the time and prompted new legislative measures in many jurisdictions worldwide. The main purpose of the directive introduced in 1965 was to set standards for drug authorisation that should be applied across all member states. The overall structure of the directive, with articles grouped under various Titles, is shown in Table 1.1. The directive also contains a large Annex that sets out the detailed requirements pertaining to the approval of human medicines in the EU. A number of amending directives and regulations have been issued that update the articles and annex for technical progress. A selection of the more significant updates is shown in Table 1.2.

The first directives regulating veterinary medicines date back to 1981. An equivalent to the human medicines directive, Directive 2001/82/EC provided the basis for regulation of veterinary medicines for almost twenty years, but this has now been replaced by Regulation (EU) 2019/6 with effect from 28 January 2022. One of the purposes of changing from a Directive to a Regulation was to remove the ability of

**Table 1.1** Content headings of the Human Medicines Directive.

Title I	Definitions
Title II	Scope
Title III	Placing on the market
	Chapter 1: Marketing authorisation
	Chapter 2: Special provisions applicable to homeopathic medicinal products
	Chapter 3: Procedures relevant to the marketing authorization
	Chapter 4: Mutual recognition procedure and decentralised procedure
Title IV	Manufacture and importation
Title V	Labelling and package leaflet
Title VI	Classification of medicinal products
Title VII	Wholesale distribution of medicinal products
Title VIII	Advertising
Title IX	Pharmacovigilance
Title X	Special provisions on medicinal products derived from human blood and plasma
Title XI	Supervision and sanctions
Title XII	Standing committee
Title XIII	General provisions
Title XIV	Final provisions
Annex I	Analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products



**Table 1.2** Selected updates of the Human Medicines Directive.

Dir. 2002/98/EC Human blood products	Amended by Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC
Dir. 2003/63/EC Annex I update	Amended by Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use
Dir. 2004/24/EC Herbal medicines	Amended by Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use
Reg. EC/1901/2006 Paediatric use	Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004
Reg. EC/1394/2007 Advanced therapy	Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004
Dir. 2009/53/EC Marketing variations	Directive 2009/53/EC of the European Parliament and of the Council of 18 June 2009 amending Directive 2001/82/EC and Directive 2001/83/EC, as regards variations to the terms of marketing authorisations for medicinal products
Dir 2011/62/EU Falsified products	Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products
Dir 2012/26/EU Pharmacovigilance	Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance

Member States to interpret the requirements of the Directive, which had led to too much variation in its application. The main headings of the regulation are shown in Table 1.3.

Some categories of medicinal products require direct regulation from EU institutions. Regulation (EC) No. 726/2004 as amended lays down Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human and veterinary use, and provides the legal basis for the operation of the European Medicines Agency. This regulation replaces a previous regulation from 1993 (Regulation No. 2309/93) that initiated this process. A summary of the main topics contained in the regulation is shown in Table 1.4.

A number of amending directives and regulations have been issued that update the articles and annexes of the base legislation for technical progress.

**Table 1.3** Content headings of the Veterinary Medicines Regulation.

<b>Chapter</b>	<b>Topic</b>
I	SUBJECT MATTER, SCOPE AND DEFINITIONS
II	MARKETING AUTHORISATIONS – GENERAL PROVISIONS AND RULES ON APPLICATIONS
Section 1	General provisions
Section 2	Dossier Requirements
Section 3	Clinical Trials
Section 4	Labelling and package leaflet
Section 5	Specific requirements for generic, hybrid, combination veterinary medical products and for applications based on informed consent and bibliographic data
Section 6	Marketing authorisations for limited market and in exceptional circumstances
Section 7	Examination of applications and basis for granting marketing authorisations
Section 8	Protection of technical documentation
III	PROCEDURES FOR MARKETING AUTHORISATIONS
Section 1	Marketing authorisations valid throughout the Union ('centralised marketing authorisations')
Section 2	Marketing authorisations valid in a single Member State ('national marketing authorisations')
Section 3	Marketing authorisations valid in several Member States ('decentralised marketing authorisations')
Section 4	Mutual recognition of national marketing authorisations
Section 5	Subsequent recognition in the mutual recognition and decentralised marketing authorisation procedures
Section 6	Review procedure
IV	POST-MARKETING AUTHORISATION MEASURES
Section 1	Union product database
Section 2	Collection of data by Member States and responsibilities of marketing authorisation holders
Section 3	Changes to the terms of the marketing authorisations
Section 4	Harmonisation of the summary of product characteristics for nationally authorised products
Section 5	Pharmacovigilance
Section 6	Union interest referral
V	HOMEOPATHIC VETERINARY MEDICINAL PRODUCTS

*(Continued)*

**Table 1.3** (Continued)

<b>Chapter</b>	<b>Topic</b>
VI	MANUFACTURING, IMPORT AND EXPORT
VII	SUPPLY AND USE
Section 1	Wholesale distribution
Section 2	Retail
Section 3	Use
Section 4	Advertising
VIII	INSPECTIONS AND CONTROLS
IX	RESTRICTIONS AND PENALTIES
X	REGULATORY NETWORK
XI	COMMON AND PROCEDURAL PROVISIONS
XII	TRANSITIONAL AND FINAL PROVISIONS
Annex I & II	Technical details on information/dossier to be provided with an application for a marketing authorisation

**Table 1.4** Content headings of Regulation (EC) 726/2004.

<b>Title</b>	<b>Topic</b>
I	Definitions & Scope
II	Authorisation and supervision of medicinal products for human use
Chapter 1	Submission and examination of applications — Authorisations
Chapter 2	Supervision and penalties
Chapter 3	Pharmacovigilance
III	Authorisation and supervision of veterinary medicinal products
Chapter 1	Submission and examination of applications — Authorisations
Chapter 2	Supervision and penalties
Chapter 3	Pharmacovigilance
IV	The European Medicines Agency – responsibilities and administrative structures
Chapter 1	Tasks of the agency
Chapter 2	Financial Provisions
Chapter 3	General Provisions governing the Agency
V	General and final provisions

Community-wide regulation of medical devices commenced with the introduction of Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices. Two further ‘base’ directives followed that covered all other medical devices: The Medical Devices Directive 93/42/EEC and The In Vitro Diagnostics Directive 98/79/EC. Two new Regulations have been published in 2017 to replace these three ‘base’ directives

---

MDR 2017/745	Regulation (EU) 2017/745 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No. 178/2002 and Regulation (EC) No. 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC
IVDR 2017/746	Regulation (EU) 2017/746 on in vitro diagnostic (IVD) medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU.

---

The new regulations fully apply to new devices from 26 May 2021 in the case of medical devices and from 26 May 2022 in the case of IVD products with some transitional provisions relating to existing devices extending up to 26 May 2027. The new regulations incorporate all previous amendments to the base directives and provide for more consistent and tighter regulation of medical devices to counter fraudulent activity that had been encountered with some devices, e.g. use of non-medical grade silicone in breast implants.

There are a number of other regulations/directives that you will need to consult as appropriate. These address topics such as good laboratory practice, good manufacturing practice, the conduct of clinical trials, orphan drugs and the use of genetically modified organisms. A list of the most relevant legislative instruments is shown in Table 1.5

### 1.4.2 US Legislation

Regulatory authority in the US derives primarily from the Federal Food, Drug, and Cosmetic Act (FDC Act). The act was originally passed into law in 1938, replacing a previous Food and Drugs Act that dated back to 1906. Impetus for approval of the FDC Act came from the drug-related death of 107 people. The victims, mainly children, had taken a sulphanilamide drug preparation that contained poisonous diethylene glycol as a solvent in order that it could be presented in a more palatable, raspberry-flavoured liquid form. The Act required for the first time that manufacturers test new drugs for safety and submit their results to the Food and Drugs Administration (FDA) for marketing approval. In addition, it authorised the FDA to conduct unannounced inspections of manufacturing facilities. Many amendments to the act have been introduced since then, the single most significant being the Kefauver–Harris amendment of 1962, which introduced the requirement that drugs must be shown to be effective as well as safe. This was the main US response to the Thalidomide disaster. The current text of the Act is maintained under Title 21, Chapter 9 of the United States Code (USC) and may be accessed at [uscode.house.gov/browse.xhtml](http://uscode.house.gov/browse.xhtml). An outline of the most relevant sections of the Act is shown in Figure 1.4.

**Table 1.5** Selected other directives and regulations of relevance.

Reg EU 534/2014 (Clinical practice)	Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
Dir 2005/28/EC (Clinical practice)	Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products
Dir 2003/94/EC (GMP Human)	Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use.
91/412/EEC (GMP Veterinary)	Commission Directive 91/412/EEC of 23 July 1991 laying down the principles and guidelines of good manufacturing practice for veterinary medicinal products
Dir 2004/10/EC (GLP)	Directive 2004/10/EC of the European Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances
Dir 2001/18/EC (GMO release)	Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC
Dir 2009/41/EC (GMO containment)	Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms
Reg EC/141/2000 (Orphan drug)	Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products
Reg EC/847/2000 (Orphan drug)	Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts 'similar medicinal product' and 'clinical superiority'
Reg EC/470/2009 (MRLs)	Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council
Reg EC 469/2009 (Patent protection)	Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products

Chapter I—Short Title

**Chapter II—Definitions**

Chapter III—Prohibited Acts and Penalties

Chapter IV—Food

**Chapter V—Drugs and Devices:**

**Subchapter A--Drugs and Devices:**

- SEC. 501. ADULTERATED DRUGS AND DEVICES
- SEC. 502. MISBRANDED DRUGS AND DEVICES
- SEC. 503. EXEMPTIONS AND CONSIDERATION FOR CERTAIN DRUGS, DEVICES, AND BIOLOGICAL PRODUCTS
- SEC. 503A. PHARMACY COMPOUNDING.
- SEC. 504. VETERINARY FEED DIRECTIVE DRUGS
- SEC. 505. NEW DRUGS
- SEC. 505A. PEDIATRIC STUDIES OF DRUGS
- SEC. 505B. RESEARCH INTO PEDIATRIC USES FOR DRUGS AND BIOLOGICAL PRODUCTS.
- SEC. 506. FAST TRACK PRODUCTS.
- SEC. 506A. MANUFACTURING CHANGES.
- SEC. 506B. REPORTS OF POSTMARKETING STUDIES.
- SEC. 506C. DISCONTINUANCE OF A LIFE-SAVING PRODUCT.
- SEC. 508. AUTHORITY TO DESIGNATE OFFICIAL NAMES
- SEC. 509. NON-APPLICABILITY TO COSMETICS
- SEC. 510. REGISTRATION OF PRODUCERS OF DRUGS AND DEVICES
- SEC. 512. NEW ANIMAL DRUGS
- SEC. 513. CLASSIFICATION OF DEVICES INTENDED FOR HUMAN USE
- SEC. 514. PERFORMANCE STANDARDS
- SEC. 515. PREMARKET APPROVAL
- SEC. 516. BANNED DEVICES
- SEC. 517. JUDICIAL REVIEW
- SEC. 518. NOTIFICATION AND OTHER REMEDIES
- SEC. 519. RECORDS AND REPORTS ON DEVICES
- SEC. 520. GENERAL PROVISIONS RESPECTING CONTROL OF DEVICES INTENDED FOR HUMAN USE
- SEC. 521. STATE AND LOCAL REQUIREMENTS RESPECTING DEVICES
- SEC. 522. POSTMARKET SURVEILLANCE
- SEC. 523. ACCREDITED PERSONS.

**Subchapter B--Drugs for Rare Diseases and Conditions**

- SEC. 525. RECOMMENDATIONS FOR INVESTIGATIONS OF DRUGS FOR RARE DISEASES OR CONDITIONS
- SEC. 526. DESIGNATION OF DRUGS FOR RARE DISEASES OR CONDITIONS
- SEC. 527. PROTECTION FOR DRUGS FOR RARE DISEASES OR CONDITIONS
- SEC. 528. OPEN PROTOCOLS FOR INVESTIGATIONS OF DRUGS FOR RARE DISEASES OR CONDITIONS

Subchapter C--Electronic Product Radiation Control

Subchapter D--Dissemination of Treatment Information

**Subchapter E--General Provisions Relating to Drugs and Devices**

- SEC. 561. EXPANDED ACCESS TO UNAPPROVED THERAPIES AND DIAGNOSTICS.
- SEC. 562. DISPUTE RESOLUTION.
- SEC. 563. CLASSIFICATION OF PRODUCTS.
- SEC. 564. AUTHORIZATION FOR MEDICAL PRODUCTS FOR USE IN EMERGENCIES.

**Figure 1.4** Content of the Food, Drug and Cosmetic Act.